Daewoong Pharmaceutical and Korean Society of Total Healthcare to Collaborate on Digital Health Verification and Academic Exchange

Academic Research and ESG Activities to Be Expanded Through Industry-Academia Collaboration

Daewoong Pharmaceutical announced on August 5 that it has signed a memorandum of understanding (MOU) with the Korean Society of Total Healthcare, establishing a cooperative system ranging from academic exchange and digital healthcare verification to ESG-related medical volunteer activities.

(From left) Jo Jungyeon, President of the Korean Society of Comprehensive Health Management; Lee Changjae, CEO of Daewoong Pharmaceutical; and Dong Seokho, Chairman of the Korean Society of Comprehensive Health Management, are taking a commemorative photo after signing a business agreement. Daewoong Pharmaceutical

Through this agreement, Daewoong Pharmaceutical and the Korean Society of Total Healthcare plan to jointly promote the following initiatives: academic activities and research advancement; consulting and verification projects related to digital healthcare diagnostic devices; medical volunteer work and ESG-linked activities; and other healthcare cooperation projects mutually agreed upon by both organizations.

Daewoong Pharmaceutical intends to expand academic events related to digital health-based medical checkups in collaboration with the Korean Society of Total Healthcare and actively invest in new digital health technologies. The Korean Society of Total Healthcare aims to secure medical reliability through clinical consulting and product verification of digital health technologies, strengthen its academic foundation, and pursue systematic product validation.

Previously, Daewoong Pharmaceutical signed an agreement with the Korea Association of Health Screening Institutions to supply digital diagnostic devices to clinic-level institutions, focusing on enhancing field-based precision screening and improving medical accessibility. Through the new agreement with the Korean Society of Total Healthcare, products under consideration for introduction can be verified in actual screening settings, and their effectiveness and reliability can be assessed based on clinical consulting and data. In particular, collaboration with the Korean Society of Total Healthcare?which includes major screening institutions such as Seoul National University Hospital Gangnam Center, Asan Medical Center, and the Korea Association of Health Promotion?is expected to serve as a crucial foundation for securing the academic validity of digital health technologies.

Dong Seokho, president of the Korean Society of Total Healthcare, stated, "We expect that the expertise of our society and Daewoong Pharmaceutical's healthcare technology capabilities will create diverse verification and research outcomes. In the future, health screenings will evolve into an integrated form by incorporating artificial intelligence (AI), genomics, and digital healthcare technologies, which will enhance screening accuracy and enable not only disease prediction and early diagnosis but also comprehensive health management."

Lee Changjae, CEO of Daewoong Pharmaceutical, said, "Through this agreement, we plan to further develop and expand the entire health management cycle?from prevention and early diagnosis to treatment and post-management?together with the Korean Society of Total Healthcare, based on Daewoong Pharmaceutical's diverse digital health technologies. We will also further solidify our core marketing strategy, the 'four-step verification,' in the field of health screening."

This content was produced with the assistance of AI translation services.